# A Study of Fruquintinib in Combination With Tislelizumab in Advanced Solid Tumors

> **NCT04577963** · PHASE1,PHASE2 · TERMINATED · sponsor: **Hutchmed** · enrollment: 52 (actual)

## Conditions studied

- Triple Negative Breast Cancer
- Endometrial Cancer
- Solid Tumor, Unspecified, Adult
- Colorectal Cancer

## Interventions

- **DRUG:** Fruquintinib
- **DRUG:** Tislelizumab

## Key facts

- **NCT ID:** NCT04577963
- **Lead sponsor:** Hutchmed
- **Sponsor class:** INDUSTRY
- **Phase:** PHASE1,PHASE2
- **Study type:** INTERVENTIONAL
- **Status:** TERMINATED
- **Start date:** 2021-08-09
- **Primary completion:** 2024-06-18
- **Final completion:** 2024-06-18
- **Target enrollment:** 52 (ACTUAL)
- **Why stopped:** At the time of study termination, both fruquintinib and tislelizumab are commercially available in the United States.
- **Last updated:** 2025-07-14

## Collaborators

- [object Object]

## Primary source

ClinicalTrials.gov registry: https://clinicaltrials.gov/study/NCT04577963

## Citation

> US National Library of Medicine, ClinicalTrials.gov registration NCT04577963, "A Study of Fruquintinib in Combination With Tislelizumab in Advanced Solid Tumors". Retrieved via AI Analytics 2026-06-01 from https://api.ai-analytics.org/clinical/NCT04577963. Licensed CC0.

---

*[Clinical trials dataset](/datasets/clinical-trials) · CC0 1.0*